Visual evoked potential changes following Botox administration in patients with blepharospasm

Basit Öğe Kaydı
dc.contributor.authorEski, Mehmet Tahir
dc.contributor.authorTeberik, Kuddusi
dc.contributor.authorSezer, Taha
dc.contributor.authorAyasli, Aziz Hudai
dc.contributor.authorÖztürk, Ayhan
dc.date.accessioned2023-07-26T11:54:00Z
dc.date.available2023-07-26T11:54:00Z
dc.date.issued2023
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractPurposeTo examine visual evoked potential (VEP) changes following botulinum toxin type A (BTA) administration in patients with blepharospasm.MethodsPatients diagnosed with blepharospasm receiving BTA administration were included in the study. Three groups, a control group and two study groups (patients examined 14 days after BTA administration-Study Group 1, and patients examined 28 days after BTA administration-Study Group 2) were evaluated. Dilated fundus examinations were performed following detailed ophthalmological examinations and VEP tests. Keypoint (Dantec, Denmark) and ISCEV criteria were adopted for pattern VEP (PVEP) recording. BTA was applied in the form of local injections at a total 15-30 units, at 2.5-5 units per injection.ResultsA mean 19.4 +/- 3.2 units of BTA was used for each eye. N70 (ms), P100 (ms), and P100 (uV) values were statistically significantly lower in both study groups following drug administrations compared to the control group (p < 0.001 for all). Significant positive correlation was observed between increased P100 amplitudes and age in the control group (p = 0.008, r = 0.200). Significant negative correlation was observed between the BTA units used and decreased P100 amplitudes in both study groups 1 and 2 following drug administrations (p = 0.017, r = - 0.180 and p = 0.043, r = - 0.153, respectively).ConclusionVEP may be an important method in the diagnosis and follow-up of blepharospasm and in determining the success of drug administration and additional therapeutic requirements.en_US
dc.identifier.doi10.1007/s10792-023-02639-9
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.pmid36652021en_US
dc.identifier.scopus2-s2.0-85146387307en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-023-02639-9
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12688
dc.identifier.wosWOS:000918822800002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorTeberik, Kuddusi
dc.institutionauthorSezer, Taha
dc.institutionauthorAyaşlı, Aziz Hudai
dc.institutionauthorÖztürk, Ayhan
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectBlepharospasm; Botulinum Toxin; Visual Evoked Potential; P100en_US
dc.subjectBotulinum Neurotoxin; Standarden_US
dc.titleVisual evoked potential changes following Botox administration in patients with blepharospasmen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
12688.pdf
Boyut:
300.14 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu